SureTrader Nadex Advertisement SureTrader
Home > Boards > US OTC > Medical - Equipment >

MultiCorp International, Inc. (MCIC)

MCIC RSS Feed
Add MCIC Price Alert      Hide Sticky   Hide Intro
Moderator: sirant, gorbec1, MLR_Lite, 4u2nv2
Search This Board: 
Last Post: 4/25/2017 12:24:11 PM - Followers: 510 - Board type: Free - Posts Today: 3


http://multicorpinternational.com


MultiCorp International, Inc. Announces the Hiring of Healthcare Executive to Become New Chief Executive Officer
45 minutes ago - DJNF
MultiCorp International, Inc. Announces the Hiring of Healthcare Executive to Become New Chief Executive Officer

Mr. David Gustafson to Take Over as CEO of Company

SUN VALLEY, CA--(Marketwired - Feb 11, 2016) - MultiCorp International, Inc, (OTC PINK: MCIC) announced today that the company has hired David Gustafson as the new CEO of the company.

The company released the following statement, "MultiCorp International, Inc. is excited to announce that Mr. David Gustafson has taken over the helm of Chief Executive Officer of the company on an interim basis. The current CEO, Mr. Paul D. Lisenby, is taking a leave of absence due to medical reasons. There is no timetable for his return. In the meantime, we welcome Mr. Gustafson aboard as our CEO to spearhead the efforts of the company in the further development of the patented migraine medicine. Mr. Gustafson's 35 years of broad based, comprehensive, professional experience in the health care industry ranging from the operation of hospitals to medical groups, to integrated health delivery systems will benefit the company in developing and managing the 4-Arm Study the FDA is requiring for the migraine medicine, move the drug into further clinical trials, and to look for additional opportunities in the healthcare field for the company that can be capitalized upon to bring in additional revenue and profits. The Board of Directors also stated that they may possibly change the name of the company to further reflect the company's direction in the healthcare sector. The BOD also stated there will be no changes to the share structure of the company at this time."

About MultiCorp International, Inc.

MultiCorp International, Inc is committed itself to the further development of the patented migraine medicine the company owns a significant percentage of. The company has received information from the U.S. Food and Drug Administration that provides the company with a clear path to further the development of the drug to bring to market. The company is currently looking to partner with a pharmaceutical company that can assist the company in bringing the migraine medicine to market. For further information please contact them at info@multicorpinternational.com

About Mr. David Gustafson

David Gustafson is an executive with over 35 years of broad based, comprehensive, professional experience in the health care industry ranging from the operation of hospitals to medical groups, to integrated health delivery systems. Hospitals he managed have ranged in size from 49 to over 300 beds. His managed care experience ranges from design and implementation of a new managed care psychiatric treatment product for a major health plan, to launch of hospital based IPAs and a specialty IPA, to providing executive leadership for a hospital operating in a very tightly structured integrated healthcare delivery system, successful start-up of an ACO, and more recently, managing two IPAs serving over 42,000 members in the Inland Empire of Southern California.

In playing out the Senior Executive's external role he has served in a variety of community organizations such as the United Way, Chamber of Commerce, and service clubs. A frequent public speaker he has served on the adjunct faculty of Concordia College, Moorhead Minnesota, and has lectured at Pepperdine University, before a variety of clubs and organizations, and at hospital association seminars.

David holds a B.A. Degree in Business from Moorhead State University in Minnesota, and a Master's Degree in Hospital Administration from the University of Minnesota, a program for which he has served as a preceptor and mentor.



https://www.linkedin.com/in/david-gustafson-5703996 
David Gustafson 
President at Gustafson + Associates, LLC 
Greater Los Angeles AreaHospital & Health Care 
Current
Gustafson + Associates, LLC, Relamatrix Group,Inc. 
Previous
NAMM California, Hemet Valley Medical Center, Phoenix Health Systems Development 
Education
Hallock High School 
Recommendations 1 person has recommended David 


Experience 
President 
Gustafson + Associates, LLC 
January 2007 – Present (9 years 2 months) 
Hospital and Healthcare related Interim Leadership, Project Management, Program Development and Company Incubation. 
Senior Corporate Ambassador 
Relamatrix Group,Inc. 
2007 – Present (9 years) 
Executive Director 
NAMM California 
July 2012 – October 2014 (2 years 4 months) 
Executive Director of PrimeCare of Temecula and Sun City. Two IPAs with 42,000 managed care members. 
Hospital CEO 
Hemet Valley Medical Center 
2005 – 2006 (1 year)Greater Los Angeles Area 
CEO of this general acute medical surgical hospital owned by a hospital district. Stimulated patient flow activity through actions resulting in improved patient throughput, increased bed availability and shortened ER wait times during a time of increasing patient volumes; reduced Left Without Being Seen rate in ER from over 14% to 3% resulting in the capture of additional revenues for this department and admissions to the hospital; implemented a variety of initiatives that improved all patient satisfaction indicators; elevated medical quality; reduced overall productive FTE’s by 3% while concurrently selectively increasing staff to accommodate regulatory compliance requirements; presided over remodel and business plan development for upgraded Radiation Oncology Department; implemented PACS system in Radiology Department as well as several other hospital wide IT initiatives 
Principal 
Phoenix Health Systems Development 
August 2003 – November 2005 (2 years 4 months)Greater Los Angeles Area 
Engaged in a variety of healthcare projects, mostly focused on business development activity. Provided leadership to a hospital in crisis averting closure by Dept. of Health Services for serious patient safety and governance deficiencies while simultaneously increasing census by over 80%. 
CEO for several different hospitals in this system 
Alta Healthcare System 
March 2002 – August 2003 (1 year 6 months)Greater Los Angeles Area 
Focused case management efforts reducing Medi-Cal denials by 20%; brought about operating efficiencies by reducing staff and virtually eliminating overtime; put one hospital on fast track to JCAHO survey readiness and received minimal Type I recommendations 
President 
Pacific Integrated Healthcare, Inc 
August 1993 – March 2002 (8 years 8 months)Greater Los Angeles Area 
Management support to physician offices, facilitating growth of practice to accommodate sale; During this time founded and concurrently operated California Osteoporosis Institute, a company that pioneered low cost, retail oriented bone densitometry in multiple sites throughout Southern California. 
CEO 
Panorama Community Hospital 
May 1990 – July 1993 (3 years 3 months)Greater Los Angeles Area 
Led hospital during time of transition from proprietary corporate ownership to local, not-for-profit control. Guided development of hospital affiliated IPA; in collaboration with an LA based IPA developed a two county primary care hospital and physician network for managed care contracting purposes. 
Consultant 
Blue Cross of California 
September 1989 – April 1990 (8 months)Greater Los Angeles Area 
Major project in the development of a revolutionary managed care product for psychiatric and chemical dependency treatment. 
CEO 
Woodview Calabasas Hospital 
February 1988 – August 1989 (1 year 7 months)Greater Los Angeles Area 
CEO of this HCA managed, psychiatric hospital. Developed new service lines and restructured management team creating new, positive organizational culture. 
CEO 
Valley Hospital Medical Center 
February 1986 – January 1988 (2 years)Greater Los Angeles Area 
CEO of this HealthWest owned institution. Initiated development and construction of on-campus MOB and 600 car parking structure; initiated micro-surgery program; established case management system focusing on appropriate utilization resulting in a 10% reduction in length of stay; introduced hospital to risk contracting; guided development of IPA. 
CEO 
Memorial Medical Center 
November 1979 – January 1986 (6 years 3 months)Sioux Falls, South Dakota Area 
CEO of this Health Central, Inc. managed community hospital. Provided leadership for and orchestrated the successful merger of the community's two hospitals; developed management team at all levels resulting in a turnaround of the organization's culture, averting a unionization attempt; initiated multiple new services. 
Volunteer Experience & Causes 
Causes David cares about: 
Animal Welfare 
Arts and Culture 
Children 
Health 
Human Rights 
Science and Technology

MultiCorp International, Inc. to Develop 4 Arm Study for Emergency Room Clinical Trials With Patented Migraine Medicine

SUN VALLEY, CA, Jan 21, 2016 (Marketwired via COMTEX) -- MultiCorp International, Inc. (otc pink:MCIC) has received a report from the U.S. Food and Drug Administration that gives the company specific guidelines in creating a 4 arm study to administer the patented migraine medicine in an emergency room setting. 

The company released the following statement: "The company has received a detailed response to the Pre-IND submission sent to the U.S. Food and Drug Administration for the further development of the patented migraine medicine the company has ownership in. The FDA has responded in supplying the company with a clear roadmap to develop a 4 arm study wherein the medicine will be dispensed in an emergency room setting for patients that enter the ER for migraine relief. This study will give the company feedback on the efficacy of the drug as compared to other medications currently being dispensed to relieve migraines. This study significantly will speed up the process to bring the product to market." 


The company also stated it is suspending all other areas of business to focus 100% on the further development of the medicine. As the migraine industry in the U.S. is currently in excess of $800 Million per year, the company feels that this medicine could capture a 10-15% market share which would place a value of the medicine at $80-$120 Million.


 

Compass Point Research to Collaborate With NDA Partners to Develop Migraine Combination Drug

 
NASHVILLE, TN, Apr 07, 2015 (Marketwired via COMTEX) -- Lori Nesbitt, PharmD, Chief Executive Officer of Compass Point Research, announced today that the company has entered into an agreement with NDA Partners LLC, a highly regarded medical product development and regulatory strategy consultancy, to collaborate in the development of a new combination drug for the treatment of migraine headaches. Compass Point has been retained by the drug sponsor, MultiCorp International, Inc., a publicly traded company located in Sun Valley, CA, to manage the product development program, and NDA Partners will provide the drug development and regulatory expertise needed to prepare a development plan for a 505(b)(2) NDA submission to the US Food & Drug Administration (FDA) and to manage a preIND meeting with the FDA review division.

The product is a combination of two currently FDA approved drugs, diphenhydramine (Benadryl(R)) and trimethobenzamide (Tebamide(R), Tigan(R)), both of which can be delivered in an oral dosage form. Diphenhydramine is used clinically in combination with other dopamine antagonists such as prochloperazine and metoclopramide as first line therapy to treat migraine headaches. Trimethobenzamide is an antiemetic used to prevent nausea and vomiting. In an emergency department-based clinical study conducted in 2005, the drug combination, delivered as a single injection intramuscularly, demonstrated pain relief, tolerability, and efficacy at 24 hours compared to subcutaneous sumatriptan.

NDA Partners has assembled a highly experienced product development team with comprehensive expertise that includes regulatory strategy, nonclinical development, toxicology, CMC, clinical pharmacology, and experience in demonstration of clinical effectiveness of new migraine treatments. The team will be led by Charles Grudzinskas, PhD, a Partner in the firm who has led efforts to develop and register dozens of new medical products, and includes David Feigal, MD, former Director, FDA Center for Devices & Radiological Health (CDRH); Jeanine Kuczik, a Partner in NDA Partners with significant experience in the development of migraine treatments; and Anthony DiSanto, PhD, former Vice President of Worldwide Drug Delivery Research & Development for the Upjohn Company.

"We are very pleased to be able to combine our extensive drug development and operational experience with world class development and regulatory experts from NDA Partners," said Dr. Nesbitt. "Together, we will deliver an outstanding solution for our client."

NDA Partners is a strategy consulting firm specializing in expert product development and regulatory advice to the medical products industry and associated service industries such as law firms, investment funds and government research agencies. The highly experienced Principals and Premier Experts of NDA Partners include two former FDA Center Directors; the former Chairman of the Medicines and Healthcare Products Regulatory Agency (MHRA) in the UK; an international team of approximately 60 former pharmaceutical industry and regulatory agency senior executives; and an extensive roster of highly proficient experts in specialized areas including nonclinical development, toxicology, pharmacokinetics, CMC, clinical development, regulatory submissions, and development program management. Services include product development and regulatory strategy, expert consulting, high-impact project teams, and virtual product development teams.

MultiCorp International, Inc. (Sun Valley, CA) is a diversified company that operates in various business sectors including property development, constructions, medical, and hospitality as well as commodities such as oil and gas, and entertainment. The vision of management for the company is to diversify into many fields wherein management's expertise, along with its strategic partner's experience, will enable it to participate in high growth markets and increase profitability.

"This is an important program for us, and we believe we have a potential break-through product under development that can provide longer-lasting relief for those suffering from migraine headaches," said Ben Friedman, Rph and President of MultiCorp International, Inc. "Compass Point has assembled an outstanding team to help us develop this product, and we look forward to working with them to fill this important medical need."

About Compass Point Research

Compass Point Research is a full-service clinical and translational research management and consulting firm. The company's focus is on facilitating all aspects of clinical trials operations for community-based healthcare providers, including drug, device, nutritional supplement and consumer product development from discovery through clinical studies, and post-approval support. In addition, Compass Point develops and coordinates multi-center outcomes and registry trials for industry sponsors, healthcare providers and payers, delivering scientifically rigorous research outcomes in an affordable environment. The company has been able to assist providers with not only eliminating a subsidy for research, but actually realizing a net profit for the department or cost center while adhering to all governing regulations and internal standard operating procedures.

                 Contact Lori A. Nesbitt, PharmD, MBA Chief Executive Officer Office: 615-522-5424 Mobile: 615-418-8987 Fax: 615-522-5401 Email: lnesbitt@compasspointresearch.com    

SOURCE: Compass Point Research

                   

(C) 2015 Marketwire L.P. All rights reserved.

 

 

Multicorp International, Inc Acquires 70% Ownership in Patented Migraine Headache Medication

 

Company Seeking Clinical Trial Partner to Begin Testing in First Quarter of 2014

SUN VALLEY, CA--(Marketwired - Dec 17, 2013) - MultiCorp International, Inc, (OTC Pink: MCIC) has acquired a 70% stake in a patented migraine medication. The company released the following statement:

"MultiCorp International, Inc has acquired a 70% ownership in a patented migraine medicine that has shown to aid in the symptoms of migraine headaches. According to www.migraine.com in the U.S. alone more than 37 million people suffer from migraines and globally over 330 million people have migraines on a constant basis. The medication was developed by a physician that MultiCorp will work closely with in order to gain FDA approval for the medication. The company plans to begin clinical trials in the first quarter of 2014 and hope to have the medication to market as soon as possible. The information on the patent can be found at http://www.faqs.org/patents/app/20090018205. Under the terms of the agreement, MultiCorp will have full authority to oversee the clinical trials of the product, marketing and selling of the medication, as well the overall business of getting the product to market as quickly as possible and retaining a 70% interest in the product. With the average cost of $145 per month in medication for migraine sufferers, the market for this product is exponential here in the U.S. and globally."

For companies wishing to assist MultiCorp in clinical trials, please email us at info@multicorpinternational.com

 


 



 

AS info DE. Dept. of Corp. 

24/7 Phone: 302-739-3073, press #8 file number 3866564
http://www.corp.delaware.gov/default.shtml
Note: Web site does not give the AS. Must call, automated 24/7, or during business hours if one wishes to speak in person. 

Company Information

 MultiCorp International, Inc
10771 Sherman Way
Sun Valley, CA 91352
Phone: (818) 255-2476
Fax: (818) 255-2122

 Transfer Agent

Signature Stock Transfer, Inc.

2632 Coachlight Ct.
Plano, TX75093
Phone972-612-4120 Fax972-612-4122

Email - signaturestocktransfer@msn.com

      

 

This board is for discussing MCIC.
Information posted either positive or negative is accepted.
Personal attacks, repetitive, off topic posts or outright flame baiting posts are not accepted.
Posts that respond to PM (One way messages) are not allowed. Vulgarity is not acceptable. Violation of ones privacy is not acceptable.

Posts in violation of the rules will be deleted. Repeat offenders will be reported to the admins of IHUB.


Rules of the board per IHUB:
http://www.investorshub.com/boards/complex_terms.asp
 

 
Share structure 


As of 8/01/15  1,392,887,031 shares outstanding : 533,784,228 Free Trading : 1750,000,000 shares Authorized.

 

SHAREHOLDERS' EQUITY, Per Company Balanced sheet
As of Sept 30, 2015 the company has 1,392,887,031
shares of common stock issued and outstanding.




 


 

 

 

  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
MCIC
Current Price
Volume:
Bid Ask Day's Range
SureTrader
PostSubject
#190770  Sticky Note Average return in the stock market is 8% 4u2nv2 03/10/17 09:50:36 PM
#188427  Sticky Note Recent DD for MCIC Migraine Path (All in jonblair77 02/28/16 07:26:55 PM
#185545  Sticky Note Compass Point Research to Collaborate With NDA Partners 4u2nv2 04/07/15 09:42:53 PM
#191651   In the past maybe.... jonblair77 04/25/17 12:24:11 PM
#191650   Always good morning to own more mcic gorbec1 04/25/17 11:32:07 AM
#191649   Good Morning Everyone GO MCIC $ $ $ $ sirant 04/25/17 09:41:49 AM
#191648   My order was for 245000 at 0020 they rich- will 04/24/17 11:15:47 AM
#191647   Well between the ttwo of us we bought gorbec1 04/24/17 10:31:12 AM
#191646   anther 245000 in long hands rich- will 04/24/17 10:03:34 AM
#191645   The "management team" for the stock not to DKLN 04/23/17 11:15:42 PM
#191644   Bipolar - no. This stock has been DKLN 04/23/17 11:12:32 PM
#191643   Never know as MCIC has gone bipolar recently. 4u2nv2 04/23/17 10:46:25 PM
#191642   At much lower prices.... jonblair77 04/23/17 10:10:55 PM
#191641   Mcic the stock to own gorbec1 04/23/17 08:14:13 PM
#191640   I guess I would have to agree with MLR_Lite 04/21/17 10:04:07 PM
#191639   While none of that is important, what is DKLN 04/21/17 07:14:48 PM
#191638   Right . Let's see . Seems like someone gorbec1 04/21/17 05:27:24 PM
#191637   700k is not a dump with the large jonblair77 04/21/17 04:40:55 PM
#191636   Another dump a thon!!!!!!!!!!! kittykat777 04/21/17 04:30:50 PM
#191635   Another arse kicking today for the "management team" DKLN 04/20/17 04:32:27 PM
#191634   Another 116 k in vault today got them gorbec1 04/20/17 04:09:45 PM
#191632   Good Morning Everyone GO MCIC $ $ $ $ sirant 04/20/17 09:33:32 AM
#191631   Thursday's arse kicking for the "management team" (in DKLN 04/19/17 09:43:54 PM
#191630   Another 300 k added this morning . gorbec1 04/19/17 07:53:28 PM
#191629   Yes, this is a long shot stock..,, Holding for jonblair77 04/19/17 02:30:37 PM
#191628   There is always HOPE as long as you MLR_Lite 04/19/17 12:51:45 PM
#191627   Hope so I'll be buying picked up gorbec1 04/19/17 10:48:53 AM
#191626   "What happened here???" - what has happened is DKLN 04/19/17 10:36:09 AM
#191625   Ouch. What happened here??? Our big buyer selling 4u2nv2 04/19/17 09:51:34 AM
#191624   Most of that is correct and has been DKLN 04/18/17 04:17:42 PM
#191623   And back to trips we go..... jonblair77 04/18/17 03:43:04 PM
#191622   Zippo volume so far today. Godzilla is DKLN 04/18/17 02:49:48 PM
#191621   .0017x.0022 GO MCIC $ $ $ $ sirant 04/18/17 02:25:53 PM
#191620   Zippo volume so far today for this POS. DKLN 04/18/17 12:09:22 PM
#191619   Remember - the "management team" gets bent DKLN 04/17/17 11:15:28 PM
#191618   Wow there that talk of ten cents seems gorbec1 04/17/17 09:04:21 PM
#191617   "Wasn't someone saying 10 cents this month? And k9narc 04/17/17 07:25:57 PM
#191616   Why in the world would anyone believe DKLN 04/17/17 02:22:50 PM
#191615   Creative news = BS (8+ years of it) DKLN 04/17/17 02:20:44 PM
#191614   Looks like we lost the little bid support jonblair77 04/17/17 02:16:59 PM
#191613   There is a fine line between being creative....and k9narc 04/17/17 12:53:37 PM
#191612   Lots of creative news from this company and jonblair77 04/17/17 12:42:39 PM
#191611   Let's hope that you are wrong about that. DKLN 04/17/17 12:04:31 PM
#191610   All of them, but the oil tank one k9narc 04/17/17 11:39:15 AM
#191609   Sorry should have said 3 stooges,forgot about the kittykat777 04/17/17 11:28:13 AM
#191608   Which bogus Pr are you referring to? jonblair77 04/17/17 10:55:28 AM
#191607   I'm sure the number of shares sold on k9narc 04/17/17 10:51:24 AM
#191605   Looks like another sell off day!259,000 sold already,somebody kittykat777 04/17/17 09:54:44 AM
#191604   Yeah cause we were super successful in that arena. MLR_Lite 04/17/17 09:37:53 AM
#191603   I expect them to sell medical division (note: DHANA 04/17/17 09:34:56 AM
#191602   Well last week was a short trading week gorbec1 04/17/17 08:54:44 AM
#191601   Not a big one , but yes, the k9narc 04/17/17 08:28:30 AM
#191600   So you expect they will sell the shell jonblair77 04/17/17 08:16:31 AM
PostSubject